Arvinas Inc ARVN:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 10:35 AM EDT
43.35quote price arrow down-2.20 (-4.83%)
Volume
33,603
52 week range
34.90 - 97.33
Loading...
  • Open44.76
  • Day High44.99
  • Day Low42.89
  • Prev Close45.55
  • 52 Week High97.33
  • 52 Week High Date11/05/21
  • 52 Week Low34.90
  • 52 Week Low Date06/14/22

Key Stats

  • Market Cap2.307B
  • Shares Out53.21M
  • 10 Day Average Volume0.38M
  • Dividend-
  • Dividend Yield-
  • Beta1.95
  • YTD % Change-47.29

KEY STATS

  • Open44.76
  • Day High44.99
  • Day Low42.89
  • Prev Close45.55
  • 52 Week High97.33
  • 52 Week High Date11/05/21
  • 52 Week Low34.90
  • 52 Week Low Date06/14/22
  • Market Cap2.307B
  • Shares Out53.21M
  • 10 Day Average Volume0.38M
  • Dividend-
  • Dividend Yield-
  • Beta1.95
  • YTD % Change-47.29

RATIOS/PROFITABILITY

  • EPS (TTM)-4.46
  • P/E (TTM)-9.73
  • Fwd P/E (NTM)-7.90
  • EBITDA (TTM)-224.59M
  • ROE (TTM)-37.20%
  • Revenue (TTM)91.12M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-255.88%
  • Debt To Equity (MRQ)0.15%

EVENTS

  • Earnings Date11/01/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Arvinas Inc

 

Profile

MORE
Arvinas, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies that degrade disease-causing proteins. It uses its proteolysis targeting chimera (PROTAC) Discovery Engine, a technology platform to engineer PROTAC targeted protein degraders that are designed to harness the body’s own natural protein disposal system to selectively remove disease-causing proteins. Its three lead product candidates are ARV-110...
Timothy Shannon M.D.
Independent Chairman of the Board
John Houston Ph.D.
President, Chief Executive Officer, Director
Sean Cassidy
Chief Financial Officer
Address
5 Science Park
New Haven, CT
06511-1966
United States

Top Peers

SYMBOLLASTCHG%CHG
FATE
Fate Therapeutics Inc
21.98-1.12-4.85%
XENE
Xenon Pharmaceuticals Inc
35.59-0.91-2.51%
ROIV
Roivant Sciences Ltd
3.18-0.15-4.50%
SAGE
SAGE Therapeutics Inc
39.12-1.11-2.76%
BCRX
BioCryst Pharmaceuticals Inc
12.29-0.61-4.76%